Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04098822
Recruiting Observational

A 3 Years Naturalistic Cohort Survey Of Virtue® Male Sling System For Male Stress Urinary Incontinence

NCT04098822 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2017-06-29
Last updated
2023-02-21

Condition(s) studied

Urinary Incontinence, Stress

Investigational drug(s) / intervention(s)

Virtue male sling

Virtue male sling: The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.

Study summary

The purpose of this study is to monitor the use of Virtue® Male Sling in a real world population and collect medical data on effectiveness and to monitor safety of Virtue® at 12 and 36 months post device implantation in men with post-prostatectomy urinary incontinence.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Implanted with the Virtue® Male Sling System Exclusion Criteria: * Refuses to be included in the survey or that their medical data will be used for research purposes. * Indication for the Virtue® Male Sling System implantation is not for the treatment of male urinary incontinence

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
CHU Angers Angers France Recruiting
Jean Minjoz Hospital Besançon France Recruiting
CHU de Caen Caen France Recruiting
Centre Hospitalier Chalon Sur Saône William Morey Chalon-sur-Saône France Recruiting
Groupe Hospitalier Henri Mendor Créteil France Terminated
Claude Huriez Hospital Lille France Withdrawn
Clinique Mutualiste de la Porte de l'Orient Lorient France Completed
Edouard Herriot Hospital Lyon France Completed
Clinique de l'Esperance Mougins France Completed
CHU Carémeau Nîmes France Recruiting
Clinique Urologique Nantes-Atlantis Saint-Herblain France Recruiting
Clinique Paul Picquet Sens France Withdrawn
Ospedale Generale Regionale F. Miull Acquaviva delle Fonti Italy Withdrawn
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04098822 on ClinicalTrials.gov ↗ ← All trials in France